Solasia Pharma, a private oncology specialized pharmaceutical company developing oncology products for Asian commercial markets, announced today the filing of a New Medical Device Application for episil® (SP-03) in Japan and China.
episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM).
Developed using the award-winning* Camurus proprietary technology FluidCrystal®, episil® is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive film that mechanically protects the sensitized and sore mucosa of the oral cavity.
Clinically demonstrated, episil® has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours.
episil® oral liquid is the only product for OM that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy.
episil® was first launched in Europe in 2009 and is today commercially available in a number of countries, including the U.S. where it was launched by key global pharmaceutical players. episil® oral liquid is a medical device class 1 in Europe and a 510(k) registered medical device in the U.S.
Solasia acquired exclusive commercialization rights in Japan and China to episil® from Camurus and had been developing since.
*FluidCrystal® was awarded the "Best innovation in formulation" prize at the CPhI Worldwide in 2013